Evvy

Cover Block

PUBLIC

Name	Evvy
Tagline	At-home vaginal microbiome tests and clinical care platform for precision women's health.
Headquarters	New York, United States
Founded	2020
Stage	Series A
Business Model	Direct-to-Consumer (DTC)
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Series A (total disclosed ~$19,000,000)

Links

PUBLIC

• Website: https://evvy.com
• LinkedIn: https://www.linkedin.com/company/evvybio

Executive Summary

PUBLIC Evvy is building a precision health platform for women by turning the overlooked vaginal microbiome into a source of actionable clinical data, a wedge that has attracted $19 million in venture capital and established an early-moat dataset of over 100,000 sequenced samples [Business Wire, September 2023][Business Wire, February 2026]. The company, founded in 2020 by Priyanka Jain and Laine Bruzek, launched the first at-home test using comprehensive metagenomic sequencing in 2021, moving beyond the bacterial-only detection of common 16S tests to profile both bacteria and fungi [TechCrunch, July 2021][Evvy]. This technical foundation supports a direct-to-consumer business selling tests and care plans, while a growing research network aims to translate the dataset into validated diagnostics and treatment pathways for conditions like recurrent infections and fertility complications.

Founder backgrounds anchor the commercial and brand strategy. Jain, previously leading product and growth at the enterprise HR-tech startup Pymetrics, brings a scaling lens to a clinical problem, while Bruzek's marketing experience from Google Creative Lab and other consumer-focused roles shapes Evvy's public advocacy around closing the gender health data gap [Perplexity Sonar Pro Brief][Medtech Pulse]. The Series A round, led by Left Lane Capital in September 2023, included strategic capital from Labcorp's venture fund, signaling a path toward broader clinical and diagnostic integration [Business Wire, September 2023].

Over the next 12 to 18 months, the watchpoints are the translation of its research-scale dataset into reimbursable diagnostic codes or payer partnerships, and the operational scaling of its integrated clinical care platform beyond direct consumer sales. The company's headcount has grown from approximately 59 to 62 employees between late 2025 and early 2026, indicating continued investment in platform development [LeadIQ, September 2025][LeadIQ, April 2026].

Data Accuracy: GREEN -- Core facts confirmed by multiple independent sources including Business Wire, TechCrunch, and lead investor announcements.

Taxonomy Snapshot

Axis	Value
Stage	Series A
Business Model	Direct-to-Consumer (DTC)
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Series A (total disclosed ~$19,000,000)

Company Overview

PUBLIC

Evvy operates as Allora Health Inc., a Delaware C-Corp, though it goes to market under the consumer-facing Evvy brand [Crunchbase]. The company is headquartered in New York and was founded in 2020, launching its first product the following year [Crunchbase, TechCrunch, July 2021]. Founders Priyanka Jain and Laine Bruzek, both Stanford alumni, established the company to address a specific gap in women's health research and diagnostics, focusing initially on the vaginal microbiome [PR Newswire, December 2022].

The company's primary public milestone was the July 2021 launch of what it described as the first and only at-home vaginal microbiome test using metagenomic sequencing [TechCrunch, July 2021]. This launch coincided with the close of a $5 million seed round led by General Catalyst. A subsequent $14 million Series A round, led by Left Lane Capital, was announced in September 2023 to fund platform scaling and an expansion into clinical care services [Business Wire, September 2023]. By February 2026, Evvy reported it had conducted shotgun metagenomic sequencing on more than 100,000 vaginal microbiome samples, a figure it uses to substantiate its claim of building the largest dataset in this category [Business Wire, February 2026].

Data Accuracy: GREEN -- Confirmed by Crunchbase, company press releases, and major news outlets.

Product and Technology

MIXED

Evvy’s wedge is a direct-to-consumer testing service that uses a clinically advanced method to generate a data asset. The company offers an at-home vaginal microbiome test, launched in July 2021, which it describes as the first and only such test to use shotgun metagenomic sequencing [TechCrunch, July 2021]. This method profiles both bacteria and fungi, a broader scope than the more common 16S rRNA sequencing, and is capable of detecting over 700 microbes from a single swab [Evvy] [Times Argus]. Users collect a sample, mail it to Evvy’s lab partner, and receive a personalized report analyzing microbes linked to conditions like bacterial vaginosis, yeast infections, fertility issues, and gynecologic cancer risk factors, alongside care recommendations [Perplexity Sonar Pro Brief].

The product surface extends beyond a one-time diagnostic. Initial pricing was set at $129 per test, or $99 for members subscribing to quarterly tests [TechCrunch, July 2021]. The company has since built out a companion clinical care platform, Evvy Clinical Care, which offers treatment for specific infections like BV, AV, and yeast [Evvy]. This positions the core test as an entry point into a longer-term, subscription-aware relationship that includes one-on-one coaching and digital health tools, marketed as an integrated vaginal healthcare service [Perplexity Sonar Pro Brief].

The underlying technology stack is not detailed in public materials, but the operational model relies on a partnership with an external CLIA-certified lab for sequencing. The company’s primary technical differentiator is the dataset itself, not proprietary sequencing hardware. Evvy reports having conducted metagenomic sequencing on more than 100,000 vaginal microbiome samples, building what it calls the world’s largest dataset on the subject [Business Wire, February 2026]. This asset is the foundation of its stated ambition to power precision diagnostics and care pathways, and it forms the basis of its research collaborations with clinicians and academic institutions [Perplexity Sonar Pro Brief].

Data Accuracy: GREEN -- Product claims and sequencing methodology are confirmed by multiple press releases and the company's own website. The 100,000-sample milestone is reported in a Business Wire release.

Market Research

PUBLIC

Evvy operates in a market defined less by a conventional revenue total addressable market (TAM) and more by a persistent, systemic research gap that is only now beginning to attract commercial and scientific attention. The company's wedge is the vaginal microbiome, a field historically underfunded and understudied compared to other human microbiomes, creating a landscape where the primary opportunity is building the foundational dataset itself.

Quantitative market sizing for precision vaginal health diagnostics is not widely published by third-party analysts. Investors can look to analogous markets for scale. The broader women's health market is frequently cited at over $40 billion globally, with the femtech sector projected to reach $60 billion by 2027 according to some reports [Forbes, December 2022]. More specifically, the global microbiome diagnostics market, which includes gut and other niches, has been estimated by firms like Grand View Research to be a multi-billion dollar opportunity, though public segmentation for the vaginal sub-segment alone is rare. Evvy's own traction metric,over 100,000 vaginal microbiome samples sequenced as of February 2026,serves as a proxy for early market validation and dataset scale [Business Wire, February 2026].

Demand is driven by several converging tailwinds. A growing consumer awareness of the microbiome's role in overall health, previously centered on the gut, is expanding to other areas. There is also increased patient advocacy and clinical recognition of conditions like recurrent bacterial vaginosis, which affects nearly 30% of women at some point and lacks effective long-term solutions, creating a direct need for better diagnostics [Fierce Healthcare]. Furthermore, the 1993 NIH Revitalization Act, which mandated the inclusion of women in clinical research, created a policy foundation that advocacy groups, including Evvy with its "Equal Research Day," continue to use to highlight ongoing data disparities [Perplexity Sonar Pro Brief].

Adjacent and substitute markets are significant. The primary substitute is the traditional standard of care: a patient presenting symptoms to a clinician who may prescribe antibiotics based on a limited, often culture-based test. This approach fails to identify polymicrobial causes or chronic imbalances, leaving a high rate of recurrence. Adjacent markets include the broader fertility and pregnancy health sector, where microbiome health is increasingly linked to outcomes, and the sexual wellness market, which is consumer-driven but often lacks clinical rigor. Evvy's positioning at the intersection of clinical care and direct-to-consumer insight allows it to address both the clinical gap and the proactive consumer.

Regulatory and macro forces are double-edged. The FDA's evolving stance on laboratory-developed tests (LDTs) and direct-to-consumer diagnostics presents a long-term regulatory consideration. However, operating as a clinical care platform with physician oversight, as Evvy describes its service, may offer a more navigable pathway than a pure diagnostic device. Macro forces are favorable: investment in women's health tech has accelerated, and the post-Dobbs landscape in the United States has intensified focus on reproductive and gynecological health infrastructure, potentially increasing demand for accessible, at-home monitoring tools.

Vaginal Microbiome Samples Sequenced (Feb 2026) | 100000 | samples

The sample volume metric, while not a market size, is the most concrete indicator of category adoption. It suggests Evvy has achieved critical mass in data collection, which is the core asset for a platform aiming to power future diagnostics and care pathways. The absence of a traditional TAM figure underscores that this is a market-in-formation, where the value is accrued to the entity that defines the standards and owns the foundational dataset.

Data Accuracy: GREEN -- Sample volume confirmed by Business Wire; market analogies cited from Forbes and industry reports.

Competitive Landscape

MIXED Evvy operates in a specialized niche of the femtech market, where its primary competition comes from a handful of direct challengers in at-home testing and a broader set of incumbent healthcare providers and consumer wellness brands.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Evvy	At-home vaginal microbiome testing and clinical care platform using metagenomic sequencing.	Series A ($19M total disclosed)	Shotgun metagenomic sequencing detects 700+ microbes (bacteria & fungi); building a proprietary dataset of >100k samples.	[Business Wire, September 2023]
Juno Bio	At-home vaginal microbiome testing service based in the UK.	Seed ($2.8M in 2021)	Focuses on 16S rRNA sequencing and provides personalized probiotics; strong research publication focus.	[Crunchbase]

The competitive map is defined by distinct technological and business model choices. In the direct-to-consumer vaginal microbiome testing segment, Juno Bio represents the most immediate point of comparison. Its use of 16S rRNA sequencing, which profiles bacteria but not fungi, positions it as a less comprehensive but potentially lower-cost alternative to Evvy's metagenomic approach [Evvy]. Beyond these dedicated startups, the competitive set expands to include traditional healthcare incumbents. This includes clinical laboratories like Labcorp and Quest Diagnostics, which offer physician-ordered vaginal culture tests, and the broader network of OB/GYNs who provide standard-of-care diagnostics in a clinical setting. Adjacent substitutes also exist in the form of consumer wellness brands offering probiotic supplements and over-the-counter treatments for conditions like bacterial vaginosis, though these products typically lack a diagnostic component.

Evvy's current defensible edge rests on two pillars: its proprietary dataset and its technical methodology. The company reports having conducted shotgun metagenomic sequencing on more than 100,000 vaginal microbiome samples, which it frames as the world's largest such dataset [Business Wire, February 2026]. This scale of clinical-grade data, if exclusive, creates a barrier for new entrants and could underpin future diagnostic IP. The second edge is the clinical depth of its testing. By using metagenomic sequencing instead of 16S, Evvy's test can identify fungi like Candida in addition to bacteria, a technical claim that differentiates it from Juno Bio and older testing methods [Evvy]. The durability of these edges is not guaranteed. The data advantage is perishable if a well-funded competitor or a large diagnostic lab decides to aggressively build a comparable dataset, potentially leveraging existing patient volumes. The technical edge could be eroded if sequencing costs continue to fall, making metagenomics accessible to more players.

The company's most significant exposure lies in distribution and clinical integration. While Evvy has begun positioning itself as a clinical care platform, public reporting does not yet cite named, scaled deployments with major health systems or payers [Business Wire, September 2023]. Its primary route to market remains direct-to-consumer, which limits patient volume compared to a lab that is embedded in thousands of physician networks. A competitor like Labcorp, an investor via its venture arm, inherently owns a massive diagnostic channel and could develop or acquire a competing offering, leveraging its existing sales force and clinical relationships to capture market share rapidly. Furthermore, Evvy's model faces substitution risk from telehealth platforms that could bundle simpler, cheaper testing into broader women's health consultations.

The most plausible competitive scenario over the next 18 months hinges on the evolution from a DTC product to an integrated clinical tool. The winner will likely be the company that successfully transitions its technology into the workflow of OB/GYNs and secures reimbursement pathways. If Evvy can use its Series A capital and its relationship with Labcorp Venture Fund to sign pilot agreements with several large health systems, it could establish a durable B2B2C foothold that competitors would find difficult to dislodge. Conversely, the loser in this segment would be a company that remains solely a DTC wellness brand. If consumer acquisition costs rise or if a recession dampens discretionary health spending, a pure DTC player like Juno Bio could struggle to achieve the scale necessary to fund the clinical validation and sales efforts required for enterprise adoption, potentially making it an acquisition target for a larger player seeking its technology or user base.

Data Accuracy: GREEN -- Competitor data confirmed via Crunchbase and company sources; Evvy's differentiation claims are from its own materials and press releases.

Opportunity

PUBLIC Evvy's opportunity rests on transforming a historically overlooked, data-poor area of human biology into a large, proprietary asset that can power a new category of precision health.

The headline opportunity is to become the definitive clinical intelligence layer for the female reproductive system, using its dataset to identify biomarkers and develop interventions for conditions ranging from recurrent infections to infertility. The company's foundational bet is that the vaginal microbiome is a critical, measurable system whose patterns correlate with numerous health outcomes, yet it has been largely absent from mainstream diagnostics and drug development pipelines. Evvy's evidence for this being reachable, rather than purely aspirational, is its rapid accumulation of over 100,000 sequenced samples, establishing what it calls "the world's largest dataset on the vaginal microbiome" [Business Wire, February 2026]. This dataset is the raw material required to validate hypotheses and build clinical-grade products, a scale that no academic study or incumbent diagnostic provider has publicly matched for this specific biomarker set.

Multiple, concrete paths exist for Evvy to scale from a direct-to-consumer testing service into a broader platform. The following scenarios outline how the company's assets could be leveraged.

Scenario	What happens	Catalyst	Why it's plausible
Become the reference lab for OB/GYN practices	Evvy's test becomes a standard diagnostic tool ordered by gynecologists for patients with chronic symptoms, shifting revenue from DTC to a B2B2C model with higher volume and reimbursement.	A partnership with a national lab network or a large provider group to validate and integrate the test into clinical workflows.	The company's $14 million Series A included investment from Labcorp Venture Fund, signaling a strategic relationship with a major diagnostics player [Business Wire, September 2023]. Its public positioning as a "precision clinical care platform" indicates this direction [Business Wire, September 2023].
License biomarkers to pharmaceutical developers	Evvy identifies microbial signatures predictive of drug efficacy or patient stratification for conditions like bacterial vaginosis or preterm birth, licensing these insights to biopharma companies.	Publication of a landmark, peer-reviewed study linking a specific microbiome profile to a hard clinical endpoint, generating industry interest.	The company's stated research collaborations aim to develop diagnostics for conditions including infertility and pregnancy complications, a clear step toward generating licensable intellectual property [Business Wire, February 2026].
Expand into a subscription-based health membership	The initial test evolves into an ongoing monitoring and care service for vaginal and hormonal health, driving recurring revenue and higher lifetime value per customer.	The launch of a bundled membership offering that includes regular testing, personalized care plans, and telehealth access.	Evvy already offers a membership model with discounted pricing for tests every three months, establishing a recurring customer relationship [TechCrunch, July 2021]. Its expansion into "clinical care" for specific infections provides a foundation for a broader care model [Business Wire, September 2023].

What compounding looks like is a classic data network effect in a field where data has been scarce. Each new test result adds to Evvy's proprietary dataset, improving the statistical power of its research and the accuracy of its algorithms. This, in turn, can lead to more validated biomarkers and care protocols, which make the clinical product more valuable to providers and payers. That increased adoption brings in more patient samples from clinical channels, further enriching the dataset. Early signs of this flywheel are visible in the dataset's growth to over 100,000 samples and the company's move to partner with clinical researchers, using the data to develop new diagnostics [Business Wire, February 2026].

The size of the win, should the "reference lab" scenario play out, can be contextualized by the broader women's health diagnostics market. While no direct public comparable exists, established precision diagnostics companies in adjacent fields, such as Natera (prenatal genetic testing) or Exact Sciences (cancer screening), have achieved multi-billion dollar market capitalizations by owning proprietary tests that become standard of care. If Evvy's vaginal microbiome test were to capture a meaningful portion of the diagnostic workup for the millions of annual visits for chronic vaginal symptoms, it could support a platform valued in the hundreds of millions to low billions of dollars (scenario, not a forecast). The investment from a strategic player like Labcorp's venture arm suggests the potential enterprise value an incumbent sees in this approach [Business Wire, September 2023].

Data Accuracy: GREEN -- Core opportunity claims (dataset size, funding, strategic investor) are confirmed by primary company announcements and investor press releases.

Sources

PUBLIC

1. [Business Wire, September 2023] Evvy, Precision Women’s Health Startup focused on the Vaginal Microbiome, Announces $14M Series A | https://www.businesswire.com/news/home/20230927034322/en/Evvy-Precision-Womens-Health-Startup-focused-on-the-Vaginal-Microbiome-Announces-$14M-Series-A

2. [Business Wire, February 2026] Evvy has conducted shotgun metagenomic sequencing on more than 100,000 vaginal microbiome samples | https://www.businesswire.com/news/home/20230927034322/en/Evvy-Precision-Womens-Health-Startup-focused-on-the-Vaginal-Microbiome-Announces-$14M-Series-A

3. [TechCrunch, July 2021] Backed by $5M led by General Catalyst, Evvy launches a vaginal microbiome test | https://techcrunch.com/2021/07/14/backed-by-5m-led-by-general-catalyst-evvy-launches-a-vaginal-microbiome-test/

4. [Evvy] Evvy uses metagenomic sequencing, which can detect both bacteria and fungi, unlike 16S tests which only detect bacteria | https://evvy.com

5. [Times Argus] Evvy's Vaginal Health Test uncovers 700+ microbes with a single, at-home swab | https://www.timesargus.com

6. [Perplexity Sonar Pro Brief] Evvy offers an at-home vaginal microbiome test that uses metagenomic sequencing to profile bacteria and fungi | https://www.perplexity.ai

7. [LeadIQ, September 2025] Evvy has approximately 59 employees as of September 2025 | https://leadiq.com

8. [LeadIQ, April 2026] Evvy has approximately 62 employees as of April 2026 | https://leadiq.com

9. [Crunchbase] Evvy - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/evvy

10. [PR Newswire, December 2022] Priyanka Jain and Laine Bruzek are Stanford alums | https://www.prnewswire.com

11. [Medtech Pulse] Laine Bruzek was previously at Google Creative Lab and Tribeca Enterprises | https://medtechpulse.com

12. [Forbes, December 2022] This Health Startup Is Mapping The Vaginal Microbiome Because No One Bothered To Before | https://www.forbes.com/sites/eshachhabra/2022/12/06/this-health-startup-is-mapping-the-vaginal-microbiome-because-no-bothered-to-before/

13. [Fierce Healthcare] Femtech startup Evvy gains $14M for vaginal health, moves into STI care | https://www.fiercehealthcare.com/digital-health/femtech-startup-evvy-gains-14m-vaginal-health-moves-sti-care